CTT Pharma offers updates on US and European patents

Tampa, FL / Access Newswire / February 25, 2025 / CTT Pharmaceutical Holdings, Inc. (OTC Pink: CTTH) received the notification of the intention to grant from the European Patent Office (EPO) for additional requests to our initial European patent. CTT Pharma has already received the intention to grant from the EPO for our delivery of Micelle, but has opted to further define and strengthen our patent for diabetes drugs. Since the patent for diabetes drugs Liraglutide has expired CTT will seek to find opportunities to use our Micelle technology for liraglutide. CTT also believes that our technology could provide an improved drug administration system for pharmaceutical companies with current diabetes drugs, which are also patented for developing medicines. Moreover, CTT works actively to strengthen our patents in the United States and Europe and will seek to submit provisional patents in 2025 to continue to protect and strengthen our technology. CTT will update shareholders on additional provisional patents once they are submitted and how to be used to help develop future.

Contact:

CTT Pharma-813-606-0060

SOURCE: CTT Pharmaceutical Holdings, Inc.

View Original Press release on Access Newswire